Shares of Lumber Liquidators Holdings, Inc. (NYSE:LL) opened at $28.9, and ended -3.28% lower at $28.05. Nearly 0.89 million shares were traded by the close, lower than its average daily volume of 1.16 million shares.Lumber Liquidators Holdings, Inc. (LL) Analyst Opinion
Lumber Liquidators Holdings, Inc. has a consensus hold rating from 12 Wall Street analysts, and the number of shares currently sold short amount to at least 15.32% of shares outstanding. The stock sank -19.44% last month and is up 78.21 this year. Wall Street is only getting neutral on the stock, with 2 of analysts who cover LL having a buy-equivalent rating. Analysts have placed a $31.73 price target on Lumber Liquidators Holdings, Inc., suggesting a 13.12% gain from recent close. It’s currently trading about -32.13% below its 52-week high.
Lumber Liquidators Holdings, Inc. (LL) failed to surprise the stock market in its last reported earnings when it earned $0.02 a piece versus the consensus-estimated $0.02. Its revenue totaled $261.66 million down -0.7% from the previous quarter.Lumber Liquidators Holdings, Inc. (NYSE:LL) Intraday View
This stock (LL) is ahead of its 52-week low with 87.12%. Its last month’s stock price volatility remained 4.01% which for the week stands at 4.37%. The share price has moved backward from its 20 days moving average, trading at a distance of -14.42% and stays -21.21% away from its 50 days moving average. Over the last five days, shares have faced -8.72% losses and now is up 2.65% since hitting its 200-day moving average of $30.99. Lumber Liquidators Holdings, Inc. (LL) has made its way to a 12-month gain of 70.31%.
Turning to ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP), its shares were trading at $4.51 a gain of $0.21, on the trading floor. The stock, after opening at $4.23, touched a high of $4.57 before paring much of its gains. So far, analysts are sticking with their neutral recommendations with the consensus call at 2.5. ZIOPHARM Oncology, Inc. has 1 buy ratings, 4 holds and 0 sells even after the stock tumbled -42.77% from its high of $ 7.88 to a $677.45 million market value through last close.
The company’s consensus rating on Reuter’s scale remained unchanged from 2.5 to 2.5 during a month. Analysts set a 12-month price target of $12.5 a share. The target implies a 177.16% spike from where the shares are currently trading. Also, the current price highlights a discount of 409.98% to analysts’ high consensus price target.ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Intraday Trading
The counter witnessed a trading volume of 2.76 million shares versus an average volume of 1.33 million shares during last trading session. Its last month’s stock price volatility remained 7.64% which for the week approaches 6.32%. The lowest price the stock reached in the last trading day was $4.035 and compares with the $4.16 52-week low. The stock recovered 8.41% since its low point and has performed -15.7% year-to-date.